POTS After Covid: The Metabolic Mechanism and What Reverses It

The Short Answer

Post-Covid POTS is your autonomic nervous system trying to compensate for a circulatory and energy supply that is operating below normal capacity. When you stand up, the energy economy you have been running on cannot meet the metabolic cost of maintaining cerebral perfusion against gravity, and the system reaches for the only mechanism available to it: tachycardia. Standard POTS treatment (compression, salt, fluids, beta blockers, ivabradine) manages the symptom downstream of the mechanism. The protocol that addresses the upstream metabolic floor is the same one that addresses the rest of your Long Covid symptoms.

What POTS Actually Is

POTS (Postural Orthostatic Tachycardia Syndrome) is defined clinically by a sustained heart rate increase of 30 or more beats per minute within 10 minutes of standing, without significant blood pressure drop, accompanied by orthostatic symptoms (lightheadedness, palpitations, fatigue, brain fog, exercise intolerance).

The diagnostic criteria are functional, not mechanistic. They describe what happens when you stand, not why. The "why" varies, which is why POTS is sometimes called a syndrome rather than a single disease.

Pre-Covid POTS subtypes include:

• Neuropathic POTS: small-fiber autonomic neuropathy preventing appropriate peripheral vasoconstriction
• Hyperadrenergic POTS: elevated norepinephrine response producing exaggerated cardiovascular reaction
• Hypovolemic POTS: reduced blood volume causing orthostatic intolerance
• Mast-cell-driven POTS: mast cell activation producing vasodilation
• Deconditioning POTS: reduced cardiovascular fitness producing exaggerated tachycardia

Post-Covid POTS overlaps with all of these and has additional mechanisms layered on top.

Why Long Covid Produces POTS

The patient population that develops POTS after Covid is overwhelmingly the same population developing the rest of the Long Covid cascade. The mechanism converges:

Reduced effective circulating volume. Long Covid patients have reduced blood volume in many studies, partly from hypothalamic dysregulation of fluid retention, partly from reduced renal sodium retention under suppressed cortisol signaling, partly from cellular dehydration secondary to the metabolic collapse. When you stand, less blood is available to maintain perfusion against gravity, and the autonomic system responds with tachycardia.

Vagal tone dysfunction. The metabolic energy deficit reduces vagal output capacity. Resting heart rates run higher, heart rate variability falls, and the autonomic balance shifts toward sympathetic dominance. The shift itself is a compensation for low effective output.

Mast cell activation. Most Long Covid patients have meaningful mast cell activation (covered in Long Covid and MCAS), which produces vasodilation and contributes to the orthostatic intolerance.

Endothelial dysfunction. Persistent SARS-CoV-2 spike RNA has been found in tissue years after infection (Peluso et al., 2024 — tissue-based evidence of persistent SARS-CoV-2 RNA and replication in post-acute sequelae, Science Translational Medicine). The mechanism by which spike protein produces vascular endothelial dysfunction and microclot formation contributes to the circulatory compromise that POTS reflects.

Cellular energy deficit. Underneath all of these is the cellular energy state. Maintaining upright posture costs more ATP than lying down. In a body operating at reduced cellular ATP supply, the cost of standing exceeds the easily available supply, and the body either reaches for tachycardia to compensate or the patient feels overwhelming need to sit down. Most do both.

This is why POTS in the Long Covid cohort behaves differently from primary POTS: it tracks the overall metabolic state. When the metabolic floor rises, the orthostatic intolerance reduces. When the patient flares, POTS symptoms intensify.

Why Standard POTS Treatment Manages But Does Not Resolve

Standard POTS treatment is generally useful and you should not stop using it without understanding what you are replacing it with. But the standard treatment is symptomatic management of the downstream effect, not resolution of the upstream cause.

• Salt and fluid loading expands circulating volume to give the autonomic system more to work with. Helpful but does not restore the cellular energy supply that is producing the inadequate response in the first place.
• Compression garments support venous return mechanically. Useful as a daily-function tool, does not address the upstream mechanism.
• Beta blockers and ivabradine reduce heart rate. Useful for symptomatic management of palpitations and tachycardia, can paradoxically worsen energy supply by reducing cardiac output further in patients whose tachycardia was actually a compensation that was working.
• Midodrine and droxidopa add peripheral vasoconstriction. Useful in neuropathic-dominant cases, less useful in metabolic-dominant cases.
• IV saline (chronic) addresses volume directly but is not a sustainable long-term strategy.

These tools are useful. They are not what reverses post-Covid POTS in the patients whose POTS is downstream of the broader metabolic collapse.

What Actually Addresses Post-Covid POTS

The Scorch Protocol addresses POTS by addressing the upstream cellular energy collapse that produced the orthostatic intolerance.

T3 therapy is the primary intervention. Restoring tissue-level T3 activity raises cellular ATP supply across all tissues, including cardiac muscle, skeletal muscle, and the autonomic ganglia. As ATP supply normalizes, the cost of upright posture becomes affordable again, and the tachycardia compensation reduces because it is no longer required. Resting heart rate falls. Heart rate variability rises. Vagal tone normalizes.

The clinical validation comes from temperature-guided SR-T3 work in CFS, the patient population most clinically adjacent to post-Covid POTS (Friedman et al., 2006 — temperature-guided SR-T3 produced clinical improvement in CFS). The protocol endpoint is basal body temperature normalization to 98.6°F, which corresponds to restored cellular T3 activity across tissues.

Dry fasting addresses the deeper pathology: the persistent spike RNA, the latent viral reservoirs, the inflammation generating the signals that are keeping the metabolic floor pressed down. The mechanism (hyperosmotic autophagy, virophagy, NK cell surge) is detailed in the dry fasting complete guide.

Refeeding and hGH rebuild the actual circulatory capacity. Mitochondrial density in cardiac muscle is restored. Endothelial function improves with time, anabolic signaling, and the cleared spike protein burden. Many POTS patients see their orthostatic symptoms reduce in this phase even before they have fully discontinued standard POTS medications.

What Recovery Looks Like

POTS symptoms typically reduce progressively as the metabolic floor rises:

• Months 0-3 (initial fast + T3 begun): symptomatic POTS treatment continues; first noticeable reduction in resting heart rate and orthostatic intolerance often appears in weeks 4-8 as T3 reaches therapeutic effect
• Months 3-6 (refeeding + hGH): meaningful reduction in tachycardia response to standing; many patients can begin tapering POTS medications
• Months 6-12 (consolidation): substantial POTS resolution in most patients; orthostatic vitals normalize
• Months 12-18+ (severe long-duration cases): structural circulatory and autonomic recovery completes

The pattern is not linear. POTS symptoms tend to flare during fasting windows and Herxheimer reactions and to reduce most noticeably during steady-state phases.

Practical Implementation Notes

Several POTS-specific considerations apply to running the Scorch Protocol in this cohort:

Hydration during the protocol. POTS patients are often on extreme daily fluid intake (3-4 liters of water plus salt) as a baseline. Dry fasting is contraindicated in this exact baseline state because the volume contraction is too aggressive. The pre-fast preparation phase needs to wean down to normal hydration (and address the underlying mechanism through medication management) before the first dry fast.

Standing tolerance during fasting. The first fasting cycles often produce worsened POTS symptoms during the fast (dehydration on top of orthostatic intolerance). Patients should plan to be horizontal for substantial portions of the fast, and the tips and tricks page covers practical management.

Medication interactions. Beta blockers and ivabradine can mask the cardiovascular signals that the protocol uses to titrate (heart rate especially). T3 dosing should be more conservative initially in patients on these medications, and the temperature endpoint should be tracked carefully because the heart rate endpoint is less reliable.

Salt loading and refeeding. As the metabolic floor rises and POTS symptoms reduce, salt loading needs to be tapered alongside the other POTS interventions. Continuing high salt intake into the recovery phase can produce its own issues; the tapering should be gradual and tracked.

Frequently Asked Questions

Can I keep my POTS medications while doing the protocol?

Yes. Beta blockers, ivabradine, midodrine, and similar POTS medications can be continued through most of the protocol and tapered as symptoms reduce. Discuss the timing with your prescribing physician.

What if my POTS is mostly hyperadrenergic?

Hyperadrenergic POTS responds well to the protocol in most cases because the elevated norepinephrine is partly a compensation for the reduced cellular energy supply. Restoring the energy supply reduces the sympathetic drive.

What about IVIG, plasmapheresis, or other immune-targeted POTS treatments?

These are appropriate for autoimmune-dominant POTS subtypes. They can be sequenced before or alongside the metabolic protocol depending on the case. They do not replace the metabolic restoration.

Will dry fasting make my POTS worse?

During the fast itself, often yes (dehydration is additive to orthostatic intolerance). After the fast, no; most patients see a net reduction in POTS symptoms 2-4 weeks post-fast. The post-fast window is where the benefit accrues.

What is the connection between POTS, MCAS, and Long Covid?

These three conditions overlap heavily because they share the same upstream metabolic collapse mechanism. Many patients have all three simultaneously. The protocol that addresses Long Covid generally addresses both MCAS and POTS. The MCAS-specific mechanism is in Long Covid and MCAS.

Where do I start?

Read the Long Covid Recovery guide for the full mechanism context, then the T3 therapy protocol page for the cellular energy restoration that drives the POTS resolution. Continue your current POTS medications until you have a stabilized baseline on the protocol.

Where to Start

If you have post-Covid POTS and have stalled on standard POTS treatment, the protocol entry is the same as for Long Covid generally, with the POTS-specific implementation modifications above. Start with the Long Covid Recovery guide.